Revolutionizing Cancer Treatment with Technology
Transgene is at the forefront of revolutionizing cancer treatment with its innovative computational tool, VacDesignR®. This advanced technology significantly enhances the efficiency and yield of designing recombinant virus-based therapeutic cancer vaccines. By optimizing vaccine design, Transgene aims to provide tailored immunotherapies that cater to individual patient needs.
The Role of VacDesignR® in Cancer Vaccines
The VacDesignR® tool represents a major advancement integrated into Transgene's INTV platform for cancer immunotherapy. Designed in-house, this computational engine specializes in refining the architecture of recombinant plasmids used in MVA (Modified Vaccinia Ankara) vectors. These vectors form the basis of individualized neoantigen therapeutic vaccines created using the myvac® platform, currently undergoing clinical trials.
Supporting Individualized Treatment Approaches
By streamlining the design and manufacturing process, VacDesignR® facilitates faster and more reliable production of neoantigen vaccines. This capability is crucial in ensuring that individualized immunotherapies are not just theoretical concepts but accessible, practical solutions for patients.
Future Enhancements and AI Integration
With future iterations, VacDesignR® is expected to include artificial intelligence components to enhance its efficiency even further. This will play a vital role in Transgene's mission to accelerate the production timelines of its therapeutic vaccines, such as TG4050, aimed at treating HPV-negative head and neck cancers after surgery.
Expert Insights from Transgene's Leadership
Maurizio Ceppi, Chief Scientific Officer of Transgene, expressed enthusiasm about showcasing the VacDesignR® tool at the upcoming ESMO AI & Digital Oncology conference. He emphasized the importance of integrating advanced technology with individualized cancer treatments, stating that Transgene is pioneering a significant shift in the oncology landscape.
Details on the Upcoming Presentation
At the ESMO AI conference, scheduled to take place in Berlin, Transgene will present a poster highlighting the capabilities of VacDesignR®. The abstract, titled "VacDesignR®: a computational tool to optimize viral-based individualized neoantigen therapeutic vaccine production," reflects the company's dedication to advancing cancer treatments through innovation.
Key Presentation Information
- Poster and Abstract number: 385P
- Session: Drug development
- Date: Mid-November, 2025
- Lead Author: B. Grellier
Transgene's Commitment to Fighting Cancer
Transgene’s approach to creating individualized cancer vaccines, through its myvac® platform, is paving the way for precision medicine in oncology. This platform tailors immunotherapies according to the specific mutations found in a patient's tumor, representing a significant evolution from traditional treatment methods.
Contact Information for Inquiries
For more information or media inquiries, you can reach:
Caroline Tosch
Corporate and Scientific Communications Manager
Phone: +33 (0)3 68 33 27 38
Email: communication@transgene.fr
Lucie Larguier
Chief Financial Officer (CFO)
Email: investorrelations@transgene.fr
Frequently Asked Questions
What is VacDesignR®?
VacDesignR® is a computational tool developed by Transgene to optimize the design and production of individualized cancer vaccines.
How does VacDesignR® benefit cancer treatment?
This tool enhances the efficiency and speed of developing personalized vaccines by streamlining the recombinant virus design process.
What is the myvac® platform?
myvac® is Transgene's platform for creating individualized cancer vaccines that target specific tumor mutations using viral vectors.
When and where will the VacDesignR® presentation take place?
The presentation is scheduled for mid-November 2025 at the ESMO AI & Digital Oncology conference in Berlin.
What role does AI play in the future of VacDesignR®?
Future versions of VacDesignR® will incorporate AI technologies to further improve performance and scalability in vaccine production.
